GYRE THERAPEUTICS, INC.GYREEarnings & Financial Report
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
GYRE Q4 FY2025 Key Financial Metrics
Revenue
$37.2M
Gross Profit
$35.5M
Operating Profit
$118.0K
Net Profit
$-1.4M
Gross Margin
95.3%
Operating Margin
0.3%
Net Margin
-3.7%
YoY Growth
33.4%
EPS
$-0.01
GYRE THERAPEUTICS, INC. Q4 FY2025 Financial Summary
GYRE THERAPEUTICS, INC. reported revenue of $37.2M (up 33.4% YoY) for Q4 FY2025, with a net profit of $-1.4M (down 340.1% YoY) (-3.7% margin). Cost of goods sold was $1.7M, operating expenses totaled $35.3M.
Key Financial Metrics
| Total Revenue | $37.2M |
|---|---|
| Net Profit | $-1.4M |
| Gross Margin | 95.3% |
| Operating Margin | 0.3% |
| Report Period | Q4 FY2025 |
GYRE THERAPEUTICS, INC. Annual Revenue by Year
GYRE THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $116.6M).
GYRE THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
GYRE THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $37.2M | +33.4% | $-1.4M | -3.7% |
| Q3 FY2025 | $30.6M | +19.9% | $5.9M | 19.4% |
| Q2 FY2025 | $26.8M | +6.1% | $1.6M | 5.9% |
| Q1 FY2025 | $22.1M | -18.8% | $3.7M | 16.9% |
| Q4 FY2024 | $27.9M | +2.7% | $569.0K | 2.0% |
| Q3 FY2024 | $25.5M | -20.5% | $2.9M | 11.2% |
| Q2 FY2024 | $25.2M | -14.0% | $4.5M | 18.0% |
| Q1 FY2024 | $27.2M | +9.0% | $9.9M | 36.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.2M | $25.2M | $25.5M | $27.9M | $22.1M | $26.8M | $30.6M | $37.2M |
| YoY Growth | 9.0% | -14.0% | -20.5% | 2.7% | -18.8% | 6.1% | 19.9% | 33.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $122.0M | $120.9M | $125.2M | $125.4M | $129.8M | $152.6M | $159.4M | $166.1M |
| Liabilities | $33.2M | $27.6M | $26.8M | $27.0M | $25.5M | $23.2M | $22.0M | $23.9M |
| Equity | $56.6M | $60.4M | $63.2M | $63.3M | $68.1M | $92.0M | $101.9M | $106.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $2.9M | $-5.5M | $1.7M | $-2.8M | $-129000 | $2.1M | $4.7M | $-5.6M |